Evolent Health Inc. (NYSE:EVH) COO Thomas Peterson III sold 72,827 shares of Evolent Health stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $21.54, for a total value of $1,568,693.58. Following the sale, the chief operating officer now owns 377,623 shares in the company, valued at $8,133,999.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Evolent Health Inc. (NYSE:EVH) opened at 22.71 on Tuesday. Evolent Health Inc. has a 52 week low of $8.14 and a 52 week high of $26.84. The stock’s market cap is $1.37 billion. The firm’s 50-day moving average price is $24.35 and its 200-day moving average price is $17.14.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.04. Evolent Health had a negative return on equity of 5.04% and a negative net margin of 76.55%. The firm had revenue of $56.50 million for the quarter, compared to the consensus estimate of $51.96 million. During the same period in the prior year, the business posted ($0.95) earnings per share. The company’s revenue for the quarter was up 443.3% on a year-over-year basis. Equities analysts predict that Evolent Health Inc. will post ($0.54) earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of EVH. Barclays PLC acquired a new stake in shares of Evolent Health during the second quarter valued at $144,000. American International Group Inc. increased its stake in shares of Evolent Health by 14.9% in the second quarter. American International Group Inc. now owns 8,761 shares of the company’s stock valued at $168,000 after buying an additional 1,134 shares during the last quarter. Nationwide Fund Advisors increased its stake in shares of Evolent Health by 8.5% in the second quarter. Nationwide Fund Advisors now owns 10,109 shares of the company’s stock valued at $194,000 after buying an additional 789 shares during the last quarter. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Evolent Health during the second quarter valued at $199,000. Finally, Alliancebernstein L.P. acquired a new stake in shares of Evolent Health during the second quarter valued at $278,000. Hedge funds and other institutional investors own 42.07% of the company’s stock.

Several equities research analysts recently weighed in on the company. Canaccord Genuity restated a “buy” rating on shares of Evolent Health in a research report on Thursday, May 26th. Leerink Swann restated an “outperform” rating and set a $20.00 price target on shares of Evolent Health in a research report on Sunday, July 17th. FBR & Co lifted their price target on Evolent Health from $16.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, July 13th. Finally, Jefferies Group assumed coverage on Evolent Health in a research report on Tuesday, July 26th. They set a “buy” rating and a $28.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $22.50.

Evolent Health Company Profile

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

5 Day Chart for NYSE:EVH

Receive News & Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.